SART3 and neoplasm: Tumor growth inhibition in groups (n = 5−7 in each group) treated with CD40L (0.92±0.28 g), SART3 (0.72±0.27 g), GM-CSF (0.60±0.40 g), CD40L+GM-CSF (0.69±0.49 g), SART3+GM-CSF (0.74±0.13 g), or SART3+CD40L (0.69±0.44 g) did not reach statistical significance compared with that in the mock control (Fig. 2D: left panel).